Clinical Trials Browser

INDUSTRY × Parkinson Disease 4, Autosomal Dominant Lewy Body × Cisplatin × Clear all

NCT07216703 2026-03-13

TroFuse-036

Phase 3 Recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Uterine Cervical Neoplasms

NCT06623422 2026-03-11

INTerpath-009

Phase 3 Recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT06788912 2026-03-10

MK-3475-01E

Phase 2 Recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Lung Neoplasms

NCT03221426 2026-03-09

KEYNOTE-585

Phase 3 Completed

1,007 enrolled 25 charts

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Stomach Neoplasms

NCT05152147 2026-02-27

HERIZON-GEA-01

Phase 3 Active not recruiting

Gastrointestinal

Adenocarcinoma Of Esophagus, Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms, Stomach Neoplasms

NCT03976323 2026-02-25

Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)

Phase 3 Completed

1,003 enrolled 23 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma

NCT04221945 2026-02-20

KEYNOTE-A18

Phase 3 Completed

1,060 enrolled 30 charts 1 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Uterine Cervical Neoplasms

NCT03829319 2026-02-05

LEAP-006

Phase 3 Completed

761 enrolled 31 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body

NCT04700124 2026-02-05

KEYNOTE-B15

Phase 3 Completed

Parkinson Disease 4, Autosomal Dominant Lewy Body, Urinary Bladder Neoplasms

NCT03040999 2026-02-04

KEYNOTE-412

Phase 3 Completed

804 enrolled 20 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT03635567 2026-02-04

KEYNOTE-826

Phase 3 Completed

617 enrolled 29 charts 1 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Uterine Cervical Neoplasms

NCT05017012 2026-01-08

MK-3475A-C18

Phase 1 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body

NCT04949256 2025-12-15

MK-7902-014

Phase 3 Active not recruiting

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma

NCT03358472 2025-12-03

Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)

Phase 3 Completed

89 enrolled 14 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT02964013 2025-10-14

KEYVIBE-001

Phase 1 Completed

474 enrolled 39 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Neoplasms

NCT04716933 2025-09-09

LEAP-006

Phase 3 Completed

201 enrolled 19 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body

NCT03924856 2025-08-28

KEYNOTE-866

Phase 3 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Urinary Bladder Neoplasms

NCT03765918 2025-08-20

MK-3475-689

Phase 3 Active not recruiting

714 enrolled 90 charts 1 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Head and Neck Neoplasms

NCT04380636 2025-08-17

MK-7339-012

Phase 3 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05007106 2025-08-14

KEYVIBE-005

Phase 2 Completed

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT05298423 2025-08-01

KEYVIBE-006

Phase 3 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT04924101 2025-07-23

KEYNOTE-B99

Phase 2 Completed

Parkinson Disease 4, Autosomal Dominant Lewy Body, Small Cell Lung Carcinoma

NCT02358031 2025-07-18

MK-3475-048

Phase 3 Completed

882 enrolled 50 charts 1 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Head and Neck Neoplasms

NCT04153565 2025-07-17

MK-3475-A17

Phase 1 Completed

19 enrolled 14 charts

Other solid neoplasmThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Mesothelioma

NCT04634877 2025-06-09

KEYNOTE-B21

Phase 3 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Endometrial Neoplasms

NCT04003636 2025-04-23

KEYNOTE-966

Phase 3 Completed

1,069 enrolled 19 charts 1 FDA

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Bile Duct Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT04924062 2025-04-17

MK-3475-966

Phase 3 Completed

158 enrolled 19 charts

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Bile Duct Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT03631784 2025-03-25

KEYNOTE-799

Phase 2 Completed

216 enrolled 15 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT04956692 2024-12-03

MK-3475-A86

Phase 3 Active not recruiting

531 enrolled 18 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT04210115 2024-11-15

KEYNOTE 975

Phase 3 Active not recruiting

Gastrointestinal

Adenocarcinoma Of Esophagus, Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma

NCT03189719 2024-10-15

KEYNOTE-590

Phase 3 Completed

749 enrolled 40 charts 1 FDA

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms

NCT03664024 2024-08-22

KEYNOTE-782

Phase 2 Completed

118 enrolled 14 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Adenocarcinoma, Carcinoma, Non-Small-Cell Lung

NCT03950674 2024-06-10

MK-3475-189

Phase 3 Completed

40 enrolled 20 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT02494583 2023-04-13

MK-3475-062

Phase 3 Completed

763 enrolled 29 charts

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Stomach Neoplasms

NCT03066778 2022-10-03

KEYNOTE-604

Phase 3 Completed

453 enrolled 23 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Small Cell Lung Carcinoma

NCT02335411 2022-08-08

KEYNOTE-059

Phase 2 Completed

318 enrolled 24 charts 1 FDA

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Stomach Neoplasms

NCT04859582 2021-12-16

KEYNOTE-859

Phase 3 Withdrawn

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Stomach Neoplasms

NCT03920839 2020-04-24

INCMGA00012 Plus Chemotherapy in Participants With Advanced Solid Tumors (POD1UM-105)

Phase 1 Withdrawn

Other solid neoplasmThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung

NCT03342352 2019-12-20

Nivolumab Plus Epacadostat in Combination With Chemotherapy Versus the EXTREME Regimen in Squamous Cell Carcinoma of the Head and Neck (CheckMate 9NA/ECHO-310)

Phase 3 Withdrawn

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT03348904 2019-06-13

Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer

Phase 3 Terminated

2 enrolled 6 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms